Harvard Bioscience Inc Stock Research

Market Summary

USD5.590.00

Market Closed

0.00%

HBIO Stock Price

HBIO RSI Chart

HBIO Valuation

Market Cap

235.8M

Price/Earnings (Trailing)

-117.1

Price/Sales (Trailing)

2.06

EV/EBITDA

65.31

Price/Free Cashflow

65.38

HBIO Price/Sales (Trailing)

HBIO Profitability

EBT Margin

-8.10%

Return on Equity

-13.18%

Return on Assets

-6.55%

Free Cashflow Yield

1.53%

HBIO Fundamentals

HBIO Revenue

Revenue (TTM)

114.5M

Revenue Y/Y

4.16%

Revenue Q/Q

5.45%

HBIO Earnings

Earnings (TTM)

-2.0M

Earnings Y/Y

109.04%

Earnings Q/Q

137.33%

Price Action

52 Week Range

1.986.29

(Low)(High)

Last 7 days

-1.6%

Last 30 days

-6.0%

Last 90 days

110.9%

Trailing 12 Months

52.7%

HBIO Financial Health

Current Ratio

2.2

Debt/Equity

0.68

Debt/Cashflow

0.02

HBIO Investor Care

Shares Dilution (1Y)

2.36%

Diluted EPS (TTM)

0.14

Peers (Alternatives to Harvard Bioscience)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	34.2B	6.9B	-15.00%	-9.16%	25.88	4.94	7.53%	9.79%
ILMN	31.1B	4.4B	-2.80%	-17.88%	-7.06	6.99	-4.49%	-677.95%
MTD	30.0B	4.0B	-12.99%	2.78%	33.8	7.59	3.66%	11.80%
PKI	14.9B	3.4B	-15.95%	-22.45%	15.51	4.44	-23.30%	29.82%
WAT	14.8B	3.0B	-15.76%	-23.40%	21.52	5	3.42%	-2.23%
MID-CAP
SMALL-CAP
PACB	3.1B	128.3M	9.46%	119.89%	-9.64	24.1	-1.69%	-82.99%
ADPT	1.0B	184.3M	-5.31%	-11.00%	-5.15	5.45	19.29%	17.33%
QTRX	733.9M	104.4M	55.39%	16.31%	-8.67	7.03	-7.50%	-28.77%
NSTG	278.8M	132.0M	-40.20%	-62.34%	-1.73	2.11	-8.69%	-26.95%
HBIO	235.8M	114.5M	-6.05%	52.73%	-117.1	2.06	-5.10%	69.01%
BNGO	212.3M	29.5M	3.16%	-60.01%	-1.52	7.19	43.94%	-51.20%
CDXS	147.4M	116.2M	-45.43%	-79.31%	-3.08	1.27	-4.78%	-132.67%
PSNL	84.2M	68.7M	-22.41%	-54.55%	-0.74	1.23	-13.98%	-40.40%
CSBR	70.6M	53.7M	7.20%	-29.59%	-22.66	1.32	14.70%	-1523.74%

Financials for Harvard Bioscience

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	1.1%	114,532,000	113,335,000	117,963,000	120,704,000	120,693,000
Gross Profit	3.6%	62,988,000	60,819,000	64,546,000	68,682,000	68,398,000
Operating Expenses	-9.3%	61,460,000	67,752,000	69,323,000	69,149,000	72,805,000
S&GA Expenses	-2.8%	24,332,000	25,041,000	26,436,000	26,800,000	25,943,000
R&D Expenses	-2.6%	12,006,000	12,329,000	12,431,000	12,328,000	11,532,000
EBITDA	-64.3%	-5,412,000	-3,294,000	815,000	-3,254,000	-
EBITDA Margin	-71.0%	-0.05	-0.03	0.01	-0.03	-
Earnings Before Taxes	89.6%	-954,000	-9,179,000	-7,156,000	-2,421,000	-6,474,000
EBT Margin	-33.5%	-0.08	-0.06	-0.02	-0.05	-
Interest Expenses	34.1%	3,103,000	2,314,000	2,270,000	1,588,000	1,502,000
Net Income	78.8%	-2,014,000	-9,516,000	-6,889,000	-3,654,000	-6,499,000
Net Income Margin	-43.8%	-0.08	-0.06	-0.03	-0.05	-
Free Cahsflow	86.0%	-438,000	-3,123,000	-4,470,000	-3,276,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	0.1%	146	145	147	155	158
Current Assets	2.6%	52.00	51.00	52.00	56.00	59.00
Cash Equivalents	-15.9%	4.00	5.00	5.00	4.00	5.00
Inventory	1.6%	27.00	26.00	26.00	29.00	29.00
Net PPE	1.7%	3.00	3.00	4.00	3.00	3.00
Goodwill	0.6%	57.00	56.00	55.00	56.00	57.00
Liabilities	-2.6%	71.00	73.00	75.00	78.00	82.00
Current Liabilities	-0.1%	23.00	23.00	21.00	23.00	27.00
Long Term Debt	1.6%	49.00	48.00	49.00	-	-
LT Debt, Current	0%	3.00	3.00	3.00	-	-
LT Debt, Non Current	-4.5%	41.00	43.00	47.00	46.00	46.00
Shareholder's Equity	2.9%	74.00	72.00	72.00	78.00	76.00
Retained Earnings	0.4%	-141	-142	-140	-137	-139
Additional Paid-In Capital	0.5%	230	229	228	227	226
Shares Outstanding	0.3%	42.00	42.00	42.00	41.00	41.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	329.7%	4,950	1,152	-1,410	-2,719	-1,761
Share Based Compensation	2.9%	4,541	4,411	4,434	4,299	4,224
Cashflow From Investing	47.7%	-831	-1,590	-1,713	-1,751	-1,515
Cashflow From Financing	-105.3%	-5,824	-2,837	2,487	2,597	2,983

Risks for HBIO

What is the probability of a big loss on HBIO?

96.5%

Probability that Harvard Bioscience stock will be more than 20% underwater in next one year

76.5%

Probability that Harvard Bioscience stock will be more than 30% underwater in next one year.

68.8%

Probability that Harvard Bioscience stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HBIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Harvard Bioscience was unfortunately bought at previous high price.

Drawdowns

Returns for HBIO

Cumulative Returns on HBIO

3.8%

10-Year Cumulative Returns

5.6%

7-Year Cumulative Returns

4.0%

5-Year Cumulative Returns

28.4%

3-Year Cumulative Returns

What are the long-term rolling returns for HBIO?

FIve years rolling returns for Harvard Bioscience.

Annualized Returns

Which funds bought or sold HBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-25	Legato Capital Management LLC	unchanged	-	96,947	284,739	0.05%
2023-05-23	ROYCE & ASSOCIATES LP	added	1.00	2,097,690	6,044,560	0.06%
2023-05-19	Anson Funds Management LP	sold off	-100	-301,274	-	-%
2023-05-18	JPMORGAN CHASE & CO	unchanged	-	2,000	4,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	23.37	187,000	401,000	-%
2023-05-16	Meros Investment Management, LP	reduced	-1.11	1,572,660	4,721,660	2.69%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	31.78	38,843	77,759	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	207,619	207,619	-%
2023-05-15	CITADEL ADVISORS LLC	reduced	-27.21	12,089	128,634	-%
2023-05-15	GEODE CAPITAL MANAGEMENT, LLC	added	-	484,899	1,423,900	-%

Latest Funds Activity

Are funds buying HBIO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own HBIO

No. of Funds

Harvard Bioscience News

Schedule 13G FIlings of Harvard Bioscience

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2023	b. riley asset management, llc	7.8%	3,264,796	SC 13G/A
Feb 15, 2023	b. riley asset management, llc	7.84%	3,264,796	SC 13G
Feb 14, 2023	harvey partners, llc	7.0%	2,911,500	SC 13G
Feb 13, 2023	punch & associates investment management, inc.	6.64%	2,764,039	SC 13G/A
Feb 13, 2023	portolan capital management, llc	2.53%	1,054,300	SC 13G/A
Jan 11, 2023	leviticus partners lp	4.93%	2,053,907	SC 13G/A
Dec 21, 2022	leviticus partners lp	5.41%	2,253,907	SC 13G
Jul 08, 2022	blackrock inc.	2.9%	1,209,119	SC 13G
Feb 14, 2022	punch & associates investment management, inc.	5.31%	2,166,775	SC 13G
Feb 11, 2022	portolan capital management, llc	6.22%	2,538,799	SC 13G/A

HBIO Fair Value

Show Fair-Value

Recent SEC filings of Harvard Bioscience

View All Filings

Date Filed	Form Type	Document
May 30, 2023	SD	SD
May 23, 2023	4	Insider Trading
May 23, 2023	4	Insider Trading
May 23, 2023	4	Insider Trading
May 23, 2023	4	Insider Trading
May 15, 2023	8-K	Current Report
Apr 26, 2023	10-Q	Quarterly Report
Apr 25, 2023	8-K	Current Report
Apr 07, 2023	ARS	ARS
Apr 05, 2023	DEF 14A	DEF 14A

Latest Insider Trading transactions for HBIO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-22	EDRICK ALAN I	acquired	-	-	25,554	-
2023-05-22	Eade Katherine A.	acquired	-	-	25,554	-
2023-05-22	LOY BERTRAND	acquired	-	-	31,516	-
2023-05-22	Loewald Thomas W	acquired	-	-	25,554	-
2023-03-15	Green James W	bought	52,000	2.6	20,000	chief executive officer
2023-03-15	EDRICK ALAN I	bought	42,423	2.62	16,192	-
2023-03-14	Green James W	bought	53,400	2.67	20,000	chief executive officer
2023-03-14	EDRICK ALAN I	bought	36,867	2.67	13,808	-
2023-03-06	Cote Jennifer	acquired	-	-	82,634	interim cfo
2023-03-06	Green James W	acquired	-	-	692,750	chief executive officer

About Harvard Bioscience

James W. Green

www.harvardbioscience.com

490

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

HBIO Income Statement

2023-03-31

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues	$ 29,975	$ 28,778
Cost of revenues	11,629	12,601
Gross profit	18,346	16,177
Sales and marketing expenses	5,978	6,687
General and administrative expenses	6,334	6,325
Research and development expenses	2,897	3,220
Amortization of intangible assets	1,388	1,466
Settlement of litigation, net - Note 14	0	5,191
Total operating expenses	16,597	22,889
Operating income (loss)	(1,749)	6,712
Other expense:
Interest expense	(974)	(384)
Other income, net	432	78
Total other expense	(542)	(306)
Income (loss) before income taxes	1,207	(7,018)
Income tax expense (benefit)	585	(138)
Net income (loss)	$ 622	$ (6,880)
Income (loss) per share:
Basic income (loss) per share (in dollars per share)	$ 0.01	$ (0.17)
Diluted income (loss) per share (in dollars per share)	$ 0.01	$ (0.17)
Weighted-average common shares:
Basic (in shares)	42,119	41,219
Diluted (in shares)	42,783	41,219

HBIO Balance Sheet

2023-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,789	$ 4,508
Accounts receivable, net	17,737	16,705
Inventories	26,861	26,439
Other current assets	4,062	3,472
Total current assets	52,449	51,124
Property, plant and equipment, net	3,424	3,366
Operating lease right-of-use assets	5,505	5,816
Goodwill	56,618	56,260
Intangible assets, net	19,641	21,014
Other long-term assets	7,941	7,780
Total assets	145,578	145,360
Current liabilities:
Current portion of long-term debt	2,970	3,811
Current portion of operating lease liabilities	2,130	2,135
Accounts payable	5,978	6,447
Deferred revenue	4,121	3,370
Other current liabilities	8,018	7,486
Total current liabilities	23,217	23,249
Long-term debt, net	41,083	43,013
Deferred tax liability	546	590
Operating lease liabilities	4,938	5,282
Other long-term liabilities	1,454	1,006
Total liabilities	71,238	73,140
Commitments and contingencies - Note 13
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 42,190,043 shares issued and outstanding at March 31, 2023; 42,081,707 shares issued and outstanding at December 31, 2022	455	454
Additional paid-in-capital	230,108	229,008
Accumulated deficit	(141,568)	(142,190)
Accumulated other comprehensive loss	(14,655)	(15,052)
Total stockholders' equity	74,340	72,220
Total liabilities and stockholders' equity	$ 145,578	$ 145,360